dc.contributor.author | Ferhatoglu, Ferhat | |
dc.contributor.author | Cil, Ibrahim | |
dc.contributor.author | Kucukarda, Ahmet | |
dc.contributor.author | Atci, Muhammed Mustafa | |
dc.contributor.author | Secmeler, Saban | |
dc.contributor.author | Paksoy, Nail | |
dc.contributor.author | Ak, Naziye | |
dc.contributor.author | Ayhan, Murat | |
dc.contributor.author | Ozyukseler, Deniz Tataroglu | |
dc.contributor.author | Onder, Arif Hakan | |
dc.contributor.author | Avci, Okan | |
dc.contributor.author | Oyman, Abdilkerim | |
dc.contributor.author | Okten, Ilker Nihat | |
dc.contributor.author | Gulturk, Ilkay | |
dc.contributor.author | Akagunduz, Baran | |
dc.contributor.author | BAŞOĞLU TÜYLÜ, TUĞBA | |
dc.contributor.author | Cakir, Emre | |
dc.contributor.author | HACIBEKİROĞLU, İLHAN | |
dc.contributor.author | Ozcelik, Melike | |
dc.contributor.author | Aydiner, Adnan | |
dc.date.accessioned | 2021-12-10T12:55:55Z | |
dc.date.available | 2021-12-10T12:55:55Z | |
dc.identifier.citation | Cil I., Kucukarda A., Atci M. M. , Secmeler S., Paksoy N., Ferhatoglu F., Ak N., Ayhan M., Ozyukseler D. T. , Onder A. H. , et al., "Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study", TUMORI JOURNAL, 2021 | |
dc.identifier.issn | 0300-8916 | |
dc.identifier.other | av_e2bbd5ab-b86a-40e1-91bd-88aec20269db | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/175025 | |
dc.identifier.uri | https://doi.org/10.1177/03008916211037739 | |
dc.description.abstract | Introduction: Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate and its survival advantage has been shown in advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, clinical trials underrepresent patients > 65 years of age, leading to a lack of information in this population. We analyzed the real-world outcomes of older women who were treated with T-DM1 therapy. Methods: We performed a multicenter, observational, retrospective analysis of patients aged > 65 years treated with T-DM1. A total of 93 patients from 10 cancer centers were involved in the study. Our goal was to determine the survival, response rates, and toxicity profile in T-DM1-treated patients, as well as the factors that influence survival. Results: Median follow-up was 12.2 months. Objective response rate was 29%. Median progression-free survival (PFS) and overall survival (OS) were 8.47 and 15.0 months, respectively. In multivariate analysis, Eastern Cooperative Oncology Group Performance Score 2 was found to be an independent prognostic factor for worse PFS (hazard ratio [HR] 1.81, p = 0.032) and OS (HR 2.33, p = 0.006). Any adverse event (AE) was seen in 92.5% of patients; grade 3 or 4 AEs were seen in 30.1%. Dose reduction or treatment discontinuation rates were 11.8% and 6.5%, respectively. Conclusion: The efficacy of T-DM1 was acceptable and it was generally well-tolerated among older patients with advanced HER2-positive breast cancer. | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Oncology | |
dc.subject | Health Sciences | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.title | Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study | |
dc.type | Makale | |
dc.relation.journal | TUMORI JOURNAL | |
dc.contributor.department | Univ Hlth Sci , , | |
dc.contributor.firstauthorID | 2717200 | |